Pembrolizumab<\/p>\n\n\n\n
Monoclonal antibodies have become one of the most important developments in modern medicine. These biologic drugs are laboratory produced antibodies designed to recognize and bind to specific targets in the body. Many monoclonal antibodies are used to treat cancer, autoimmune diseases, and inflammatory disorders. One of the most successful monoclonal antibody drugs currently used in medicine is pembrolizumab. It is a humanized monoclonal antibody that has transformed cancer treatment by helping the immune system recognize and destroy cancer cells. Since its approval by the United States FDA in 2014, pembrolizumab has become widely used in the treatment of multiple forms of cancer and is considered a major advancement in cancer immunotherapy (1).
<\/p>\n\n\n\n
Pembrolizumab is manufactured by Merck Sharp and Dohme Corp. The drug was first approved by the FDA in September 2014 for the treatment of advanced melanoma (1). Since then, additional approvals have expanded its use to several other cancers including non-small cell lung cancer, head and neck squamous cell carcinoma, classical hodgkin lymphoma, cervical cancer, urothelial carcinoma, renal cell carcinoma, endometrial cancer, and tumors classified as microsatellite instability high or mismatch repair deficient (2). Pembrolizumab belongs to the class of drugs known as immune checkpoint inhibitors. More specifically, it is a programmed cell death protein inhibitor (PD-1). Cancer cells often avoid destruction by the immune system by activating inhibitory pathways that suppress t cell function. Pembrolizumab blocks this suppression and allows immune cells to attack tumor cells more effectively (3). The medication is administered in an IV, usually as a 30 minute infusion. The standard adult dosage is 200 mg every three weeks or 400 mg every six weeks depending on the patient’s treatment plan and cancer type (2). Treatment duration varies depending on disease progression, side effects, and patient response. Some patients continue therapy for months or even years. <\/p>\n\n\n\n
<\/p>\n\n\n\n
Pembrolizumab is primarily used to treat cancer. One of the earliest diseases successfully treated with pembrolizumab was advanced melanoma, an aggressive form of skin cancer associated with high mortality rates (1). Melanoma develops from melanocytes. Before immune checkpoint inhibitors were introduced, treatment options for advanced melanoma were limited and survival rates were poor. Another major use of pembrolizumab is in non-small cell lung cancer (NSCLC), which accounts for approximately 85% lung cancer cases (3). Pembrolizumab is often prescribed for patients whose tumors express high levels of the PD-L1 protein. By blocking PD-1 signaling, the drug improves immune recognition of lung cancer cells and can significantly increase survival rates. Additional FDA approvals have expanded use into cancers of the bladder, cervix, kidneys, endometrium, and head\/neck regions (2). Unlike medications used for inherited disorders or autoimmune disease, pembrolizumab is primarily designed for oncology applications. However, because it strongly stimulates immune activity the drug can sometimes produce autoimmune-like side effects due to increased immune system activation against normal tissues.
<\/p>\n\n\n\n
Pembrolizumab is classified as an IgG4 monoclonal antibody. Immunoglobulin G antibodies are the most abundant antibodies in human blood circulation and are responsible for long term immune defense. IgG antibodies contain two antigen binding Fab regions and one Fc region. The Fab regions recognize specific antigens, while the Fc region interacts with immune cells and other components of the immune system. The IgG4 subclass was selected for pembrolizumab because it produces reduced inflammatory activation compared to other antibody subclasses such as IgG1. This is important because the primary goal of pembrolizumab is to block the PD-1 receptor rather than directly destroy cells through complement activation (5).
<\/p>\n\n\n\n
Pembrolizumab works by targeting the PD-1 receptor found on T lymphocytes. Under normal conditions, PD-1 functions as an immune checkpoint that prevents excessive immune responses and protects health tissues known as PD-L1 and PD-L2 on their surfaces. When PD- L1 binds to PD-1, T-cell activity becomes suppressed and immune cells are unable to attack the tumor effectively (3). Pembrolizumab binds directly to the PD-1 receptor and blocks interaction with PD-L1 and PD-L2. This prevents cancer cells from turning off T cells. As a result, T lymphocytes remain active and are able to recognize, target, and destroy malignant cells (5). Because pembrolizumab enhances immune system activity, many patients experience tumor shrinkage and longer survival times. In some cancers, pembrolizumab has produced durable responses lasting years after treatment initiation. This mechanism has significantly changed the field of oncology by shifting treatment approaches toward immune based therapies rather than only chemotherapy or radiation.
<\/p>\n\n\n\n
Although pembrolizumab has improved survival outcomes for many patients, it can also cause serious adverse effects. Since the drug stimulates immune responses, the immune system may attack healthy tissues in addition to cancer cells. These complications are known as immune related adverse events (2). One severe side effect is pneumonitis, which is inflammation of lung tissue that can interfere with breathing and oxygen exchange. Other serious complications include hepatitis, nephritis, colitis, thyroid dysfunction, adrenal insufficiency, and severe skin reactions (2). Some patients may develop type 1 diabetes mellitus due to immune mediated pancreatic damage. In severe cases, pembrolizumab treatment must be permanently discontinued. Because of these risks, patients receiving pembrolizumab require careful monitoring throughout treatment. Physicians routinely evaluate organ function, hormone levels, and signs of inflammation to identify complications early.
<\/p>\n\n\n\n
Pembrolizumab is one of the most important monoclonal antibody therapies currently used in medicine. As an IgG4 monoclonal antibody targeting the PD-1 immune checkpoint, the drug has revolutionized treatment for multiple cancers including melanoma, lung cancer, and several others. Although the drug can cause serious immune related side effects, its benefits in improving survival and disease control have made it a cornerstone of modern cancer immunotherapy. The development of pembrolizumab demonstrates how monoclonal antibodies continue to transform medicine and provide new treatment options for patients with previously difficult to treat cancers.
<\/p>\n\n\n\n
References<\/p>\n\n\n\n
Pembrolizumab Monoclonal antibodies have become one of the most important developments in modern medicine. These biologic drugs are laboratory produced antibodies designed to recognize and bind to specific targets in the body. Many monoclonal antibodies are used to treat cancer, autoimmune diseases, and inflammatory disorders. One of the most successful monoclonal antibody drugs currently used… <\/p>\n